Meeting
2020 ASCO Virtual Scientific Program
KRT‑232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti–PD‑1/L1 immunotherapy.
Authors
Michael K.K. Wong
University of Texas MD Anderson Cancer Center, Houston, TX
Michael K.K. Wong , Ciara Marie Kelly , Melissa Amber Burgess , Karl Lewis , Jaspreet Singh Grewal , Anthony J. Olszanski , Jesse McGreivy , Wayne Rothbaum , Hope Qamoos , James A. DeCaprio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Other Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT03787602
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10072)
DOI
10.1200/JCO.2020.38.15_suppl.10072
Abstract #
10072
Poster Bd #
421
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.
First Author: Michael K.K. Wong
Poster
2023 ASCO Annual Meeting
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.
First Author: Alexander Peltzer
Poster
2019 ASCO Annual Meeting
MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001).
First Author: Meng XU WELLIVER
Poster
2019 ASCO Annual Meeting
An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma (MCC) who have failed treatment with anti-PD-1/L1 immunotherapy.
First Author: Glenn J. Hanna